Overview Effect of Tepotinib on the Pharmacokinetics (PK) of the P-glycoprotein (P-gp) Substrate Dabigatran Etexilate Status: Completed Trial end date: 2018-08-27 Target enrollment: Participant gender: Summary This study will investigate the effect of Tepotinib on the pharmacokinetics (PK) of the p-glycoprotein (P-gp) probe substrate Dabigatran etexilate. Phase: Phase 1 Details Lead Sponsor: Merck KGaAMerck KGaA, Darmstadt, GermanyTreatments: DabigatranKrestinTepotinib